Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
NCT01203917
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
1060
Enrollment
INDUSTRY
Sponsor class
Conditions
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Interventions
DRUG:
Gefitinib
Sponsor
AstraZeneca